Antimicrobials Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Antibacterial, Antifungal, Antiviral & Others), By Origin (Natural, Semi-Synthetic, Synthetic), By Dosage (Powder, Tablet, Solution, Liquid & Others), By Route of Administration (Oral, Topical, Parenteral & Others), By End-Users (Clinic, Hospital, Others), and Region

Antimicrobials Market size was valued at US$ 38,298.4 million in 2023 and is poised to grow at 4.6% CAGR from 2024 – 2030. Antimicrobials are substances that kill or prevent the growth of microorganisms like bacteria and mold. They can be used to treat or prevent infections in humans, animals, and plants. Antimicrobials can be natural, semisynthetic, or synthetic. The increasing cost of healthcare, which contributes to infrastructural improvements, is an important element impacting the market's growth rate. The key market drivers of market are growing awareness of health, as awareness of health issues increases so as the demand for antimicrobial products also increases, growing number of aging population, advancements in medical technology which will continue to drive the growth of antimicrobial market.

However, some restraints which will hamper the antimicrobial market are high cost, lack of infrastructure, emergence of antimicrobial resistance in human beings, durability of antimicrobial coatings in the products, lack of skill labour for doing antimicrobial coatings. The growing opportunities of antimicrobial market is in the segment of food and beverage industry where antimicrobial agents are used to extend shelf life to ensure the food safety and technological advancements, such as the development of novel antimicrobial materials and nanotechnology-based agents are further propelling market growth. Additionally, some key trends of antimicrobial market are antimicrobial additives and antimicrobial packaging which is growing due to flexibility of materials used by recycling technologies.

Key Developments

• In 2014 & 2019, The FDA authorised 20 novel antimicrobial medications ,17 of which were effective against ESKAPE bacteria, which the CDC and WHO have classified as urgent concerns.
• In October 2021, Sandoz, a Novartis unit, purchased GSK's cephalosporin antibiotic business, with rights to three well-known drugs (Zinnat, Zinacef, and Fortum) in more than 100 countries, it has cemented its place as the leading antibiotics firm globally.